Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65756 | 0.95 | ALDH1A1 (0.40) | ALDH1A1KDM4EHPGDENPP2SMN1; SMN2 | |
| SCHEMBL55921 | 0.87 | KDM4E (0.41) | ALDH1A1KDM4EHPGDENPP2MAPT | |
| SCHEMBL65670 | 0.87 | KDM4E (0.41) | ALDH1A1KDM4EHPGDENPP2MAPT | |
| SCHEMBL66082 | 0.84 | ENPP2 (0.41) | ALDH1A1KDM4EHPGDENPP2MAPT | |
| SCHEMBL57774 | 0.83 | USP2 (0.44) | ALDH1A1KDM4EHPGDENPP2SMN1; SMN2 | |
| SCHEMBL66515 | 0.80 | USP2 (0.41) | ALDH1A1ENPP2SMN1; SMN2SCD | |
| SCHEMBL14683241 | 0.76 | ENPP2 (0.53) | ALDH1A1KDM4EHPGDENPP2SMN1; SMN2 | |
| SCHEMBL8242901 | 0.76 | ALDH1A1 (0.36) | ALDH1A1ENPP2 | |
| SCHEMBL15393601 | 0.74 | ENPP2 (0.52) | ALDH1A1KDM4EHPGDENPP2SMN1; SMN2 | |
| SCHEMBL2626334 | 0.74 | SCN9A (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129546-B2 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129546-B2 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110077269-A1 | DERIVATIVES FOR MODULATION OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077269-A1 | DERIVATIVES FOR MODULATION OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
| US-7842819-B2 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842819-B2 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-20070203122-A1 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| US-20070203122-A1 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203122-A1 | Derivatives for modulation of ion channels | TRPV1, TRPA1, TRPV2 | ALDH1A1 3010/4885KDM4E 3285/4885HPGD 1667/4885 |
| US-20110077269-A1 | DERIVATIVES FOR MODULATION OF ION CHANNELS | TRPV1, TRPA1, TRPV2 | ALDH1A1 3010/4885KDM4E 3285/4885HPGD 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.